BioArctic and its partner Eisai presented data on the drug candidate lecanemab (BAN2401) – an investigational anti-amyloid-beta (Aβ) protofibril antibody being developed for the treatment of ...
BioArctic and partner Eisai held several oral presentations at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) conference, November 9-12, 2021, revealing new data on lecanemab ...
BioArctic AB’s partner Eisai held several presentations at the Alzheimer’s Association International Conference (AAIC) in Denver, Colorado July 26 to 30, 2021. The presentations included the ...
On May 4 at 9:30 CET, BioArctic’s VP Communications and Investor Relations, Oskar Bosson, presented BioArctic at a Capital Markets Day hosted by Aktiespararna. The presentation ...
BioArctic AB and its partner Eisai presented new data on the drug candidate lecanemab (BAN2401) at the 15th International Conference on Alzheimer’s and Parkinson’s Diseases and ...
On November 25 at 10:05 CET, BioArctic's VP Communications and Investor Relations, Oskar Bosson, presented BioArctic at a Capital Markets Day hosted by Erik Penser Bank. ...
On November 18 at 08:00 CET, BioArctic's CEO, Gunilla Osswald, presented BioArctic at Avanza's Capital Markets Day 2020. The presentation was broadcasted live via this link ...
BioArctic's partner Eisai presented new data on the drug candidate BAN2401 (lecanemab) at the Clinical Trials on Alzheimer’s Disease conference (CTAD), November 4-7. The presentations included ...
BioArctic’s partner Eisai presented the latest data from the open-label extension of the Phase 2b study with the investigational BAN2401 in early Alzheimer’s disease. The preliminary ...
Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm. Redeye interviewed Gunilla Osswald, CEO, and talked about innovation, sustainability and how BioArctic can ...
Gunilla Osswald, CEO, presented BioArctic and answered questions at the Stockholm Corporate Finance Life Science Seminar in Stockholm, Sweden. Link to BioArctic presentation and question and ...
Presentations related to BAN2401 were given at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held December 4-7 in San Diego, USA. BioArctic’s partner Eisai presented ...
Gunilla Osswald, CEO, presents BioArctic and participates in a panel discussion at the Redeye Neurology Seminar in Stockholm, Sweden. BioArctic presentation (in Swedish) Panel discussion (in ...
Gunilla Osswald, CEO, presented BioArctic at the Redeye Growth Day in Stockholm, Sweden. Video (in Swedish) EFN Interview (in Swedish) https://www.efn.se/bors-finans/biorctic-ser-framgangar-inom-samtliga-omraden/
BioArctic announced on February 4 that Eisai will initiate Phase 3 confirmatory study with BAN2401 in early Alzheimer’s Disease. Interview with CEO Gunilla Osswald here.
Gunilla Osswald, CEO of BioArctic AB, presented the company at the 11th Annual European Life Sciences CEO Forum & Exhibition for Partnering & Investing in Biotech ...
Gunilla Osswald, PhD, CEO, and Lars Lannfelt, Professor, MD, Senior Advisor and Co-Founder presented BioArctic at Evercore ISI in New York. The lunch meeting took place ...